Summary
This retrospective study aimed to evaluate clinical outcomes in patients receiving veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock (CS), comparing acute myocardial infarction-related cardiogenic shock (AMI-CS) with non-AMI-CS. Analysis of data from 667 patients treated between 2008 and 2023 showed that AMI-CS was associated with significantly lower in-hospital mortality compared to non-AMI-CS. Independent predictors of favorable outcomes included younger age, shorter duration of cardiac arrest, absence of severe left ventricular dysfunction, lack of renal replacement therapy, higher hemoglobin and arterial pH levels, and lower lactate levels. The findings underscore VA-ECMO’s role in improving outcomes particularly in AMI-CS patients.
Key Points
-
Clinical Context of VA-ECMO: VA-ECMO is increasingly utilized for cardiogenic shock, offering rapid hemodynamic stabilization. However, its efficacy and indications, particularly regarding different etiologies like acute myocardial infarction (AMI), remain contentious.
-
Study Population and Design: This single-center retrospective cohort study analyzed 667 patients treated with peripheral VA-ECMO for CS between 2008–2023, categorizing patients into AMI-CS (39.6%) and non-AMI-CS (60.4%) groups.
-
Baseline Clinical Differences: Compared to non-AMI-CS patients, AMI-CS patients were older, predominantly male, had higher incidences of pre-ECMO cardiac arrest, lower left ventricular ejection fractions, and better baseline hemoglobin and platelet counts.
-
Mortality Outcomes: Patients with AMI-CS exhibited significantly lower in-hospital mortality (58.6%) compared to non-AMI-CS patients (69.7%). This mortality difference remained robust even after adjusting for potential confounders through propensity-score matching.
-
Predictors of Clinical Outcomes: Independent factors predicting improved survival included younger age, shorter duration of cardiac arrest, absence of severe left ventricular dysfunction, no requirement for renal replacement therapy, higher hemoglobin levels, higher arterial pH, and lower serum lactate levels.
-
Impact of Cardiac Arrest: A significant proportion (32.8%) of patients died within 24 hours of ECMO initiation. Early deaths were associated with older age, higher rates of cardiac arrest, lower arterial pH, and higher lactate levels, indicating the severity of their initial condition.
-
Influence of Cardiac Replacement Therapies: Long-term cardiac replacement therapies (heart transplantation or ventricular assist devices) were utilized more frequently among survivors in the non-AMI-CS group, highlighting different management strategies based on CS etiology.
-
Time-Series Trends: The use of VA-ECMO increased over time, alongside improvements in clinical outcomes, notably within the AMI-CS group, likely driven by advancements in ECMO technologies and supportive care practices.
-
Real-World vs. Randomized Clinical Trials: The study underscores discrepancies between real-world observational studies and randomized clinical trials regarding mortality rates, highlighting the greater severity and complexity of cases typically encountered in routine clinical practice.
-
Clinical Implications and Recommendations: Given the superior outcomes for AMI-CS patients receiving VA-ECMO, careful patient selection, timely initiation, and tailored adjunctive therapies (such as prompt coronary revascularization) are recommended for optimal outcomes.
Conclusion
In this real-world observational study, VA-ECMO demonstrated significantly lower in-hospital mortality for patients experiencing AMI-related cardiogenic shock compared to other etiologies. The identification of robust predictors for favorable outcomes further emphasizes the importance of individualized patient management, timely ECMO initiation, and comprehensive supportive care.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Upcoming events
